Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an artificial intelligence-driven precision cardiovascular medicine company, has released a whitepaper examining the diagnostic challenges associated with non-obstructive coronary artery disease, or NOCAD, a condition in which patients experience symptoms of coronary disease without significant blockages in the major coronary arteries. The announcement, detailed in the company's Cardio Diagnostics Holdings (NASDAQ: CDIO) disclosure, matters because it targets a category of heart disease that standard testing is structurally poorly suited to catch.
At the center of the report is invasive coronary angiography, which evaluates coronary anatomy rather than function. According to the whitepaper, that limitation helps explain why some patients with symptoms of coronary disease go undiagnosed. The report specifically highlights ischemia with no obstructive coronary arteries, known as INOCA, a condition estimated to affect 3 million to 4 million Americans. The full press release is available at https://ibn.fm/N5RnS.
The whitepaper examines NOCAD subgroups, diagnostic pathways and opportunities to improve detection of coronary disease that may not be identified through conventional angiography. It also outlines clinical approaches to identifying patients earlier, including the potential role of epigenetics-based testing in primary care. That focus on the primary care setting is significant: it suggests a shift toward screening and triage tools that could flag at-risk patients before they reach the catheterization lab, where anatomy-focused imaging may return unremarkable results.
Cardio Diagnostics also used the release to highlight its ongoing efforts to build clinical evidence supporting PrecisionCHD, its AI- and epigenetics-based blood test designed to aid in diagnosing coronary heart disease. The company pointed to the test's potential application in identifying patients with INOCA whose symptoms remain unexplained by traditional testing. If such a blood-based approach proves out in clinical evidence, it could offer a less invasive and more accessible alternative to angiography for a subset of symptomatic patients, though the company's language frames this as potential rather than established clinical utility.
For investors, the whitepaper functions as both a scientific positioning exercise and a market signal. Cardio Diagnostics describes itself as an AI-powered precision cardiovascular medicine company formed to develop and commercialize clinical tests built on a proprietary AI-driven Integrated Genetic-Epigenetic Engine, or Core Technology, with the stated aim of becoming a leading medical technology company for prevention, detection and treatment of cardiovascular disease. The latest news and updates relating to CDIO are available in the company's newsroom at https://ibn.fm/CDIO. The broader reach of such corporate announcements is amplified through platforms such as BioMedWire, which operates within the Dynamic Brand Portfolio of brands at IBN.
The clinical stakes are substantial. Coronary disease that escapes detection because major arteries appear clear can leave patients without a clear explanation for their symptoms and without a management plan. By drawing attention to INOCA and the functional limitations of anatomy-based imaging, the whitepaper adds pressure on the diagnostic pathway to account for coronary function, not just structure. Whether epigenetics-based blood testing becomes part of that pathway will depend on the clinical evidence Cardio Diagnostics says it is building. Readers seeking the company's full disclosures can review the terms posted at https://www.BioMedWire.com/Disclaimer.
